GRAIL

Global and Regional MRD Testing Market Analysis Report 2024: Revolutionizing Cancer Patient Management, Rising Consumer Awareness Spurs Demand for MRD Testing - Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Surgery, Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Radiology, Health, Oncology, Hospital, PCR, Flow cytometry, Chronic leukemia, Growth, Bone marrow, Incidence, Integration, Patient, NGS, IDT, Research, Health care, Multiple myeloma, Acquisition, Cancer, Medicare, Medicine, Karyotype, MRD, Haematopoietic system, Region, GRAIL, Throttle position sensor, Lymphoma, Polymerase chain reaction, Medical imaging

The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis.
  • In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing.
  • The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients.

ILLUMINA ALERT: Bragar Eagel & Squire, P.C. is Investigating Illumina, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 27, 2024
Complaint, Acquisition, Icahn, Telephone, News, GRAIL, Defendant, P.C, Cryptocurrency

Our investigation concerns whether the board of directors of Illumina have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Illumina have breached their fiduciary duties to the company.
  • Then, on October 17, 2023, Carl Icahn (“Icahn”) filed a complaint against current and former directors of Illumina, alleging direct and derivative claims of breaches of fiduciary duty.
  • The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
  • There is no cost or obligation to you.

Getlabs to Add GRAIL's GalleriⓇ Multi-Cancer Early Detection Test to Suite of At-Home Diagnostic Services

Retrieved on: 
Thursday, February 15, 2024
Liver, Collection, Cancer, Prostate, Lung, Survival rate, Breast, Health, Nucleic acid thermodynamics, GRAIL, Patient, DNA, Partnership, Vaccine

MIAMI, Feb. 15, 2024 /PRNewswire/ -- Getlabs , the nationwide leader for at-home diagnostics, today announced that it will be adding GRAIL's GalleriⓇ multi-cancer early detection test to its list of test offerings.

Key Points: 
  • MIAMI, Feb. 15, 2024 /PRNewswire/ -- Getlabs , the nationwide leader for at-home diagnostics, today announced that it will be adding GRAIL's GalleriⓇ multi-cancer early detection test to its list of test offerings.
  • The Galleri test is a significant advancement in multi-cancer early detection screening.
  • "By leveraging our expertise in at-home diagnostic collections, we can greatly expand access to critical cancer screening services.
  • Our partnership with GRAIL represents a step forward in saving lives through early cancer detection."

Curative Insurance Company Adds GRAIL’s Galleri® Test to Member Benefits for Multi-Cancer Early Detection

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Health Technology, Oncology, Partnership, Telehealth, Navigator, DNA, PPO, Prescription, Plasma protein binding, GRAIL, Death, Risk, Cancer, Health care, Liver, Insurance, Health insurance

Curative Insurance Company , a pioneering healthcare services company, and GRAIL , LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test to eligible insurance plan members.

Key Points: 
  • Curative Insurance Company , a pioneering healthcare services company, and GRAIL , LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test to eligible insurance plan members.
  • Studies have shown a 75% sensitivity for screening cancers responsible for two-thirds of cancer deaths, rising as high as 80% for the most serious cancers.
  • This is not just about early detection; it's also about empowering our members with the tools to be proactive with their health.
  • To learn more about Curative's revolutionary health insurance plan and how it can benefit employers and employees alike, visit https://curative.com/ .

Manulife Named to 2024 Corporate Knights Global 100

Retrieved on: 
Wednesday, January 17, 2024
Insurance, Vitality, MFC, Health, Agriculture, ESG, Knight, Environment, Investment, TSX, GICS, Manulife, The Global 100, GRAIL, Corporate Knights

Ranking fourth within the Insurance industry, Manulife recognized for performance in sustainable revenues and investments

Key Points: 
  • Ranking fourth within the Insurance industry, Manulife recognized for performance in sustainable revenues and investments
    DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ - Manulife (TSX: MFC) has been named to the 2024 Corporate Knights Global 100 rankings as one of the world's most sustainable companies.
  • Manulife's performance in the Global 100 assessment was driven largely through revenues earned from sustainable sources.
  • Corporate Knights also recognized Manulife's strong long-term focus on diversity at the Board and executive management levels, and in connecting sustainability to compensation and performance.
  • In addition to being named to this year's Global 100, Manulife has also been recognized by Corporate Knights as one of Canada's Top 50 Companies for the last three years.

Manulife Named to 2024 Corporate Knights Global 100

Retrieved on: 
Wednesday, January 17, 2024
Insurance, Vitality, MFC, Health, Agriculture, ESG, Knight, Environment, Investment, TSX, GICS, Manulife, The Global 100, GRAIL, Corporate Knights

DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ -- Manulife (TSX: MFC) has been named to the 2024 Corporate Knights Global 100 rankings as one of the world's most sustainable companies. Now in its 20th year, the Global 100 quantitatively compares and ranks how the world's largest publicly traded companies embrace sustainability as part of its strategy, equally emphasizing the impact of a company's operations along with its core products and services on people and the planet. The ranking is based on a rigorous assessment of 6,720 companies with more than US$1 billion in annual gross revenues.  

Key Points: 
  • Ranking fourth within the Insurance industry, Manulife recognized for performance in sustainable revenues and investments
    DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ -- Manulife (TSX: MFC) has been named to the 2024 Corporate Knights Global 100 rankings as one of the world's most sustainable companies.
  • Manulife's performance in the Global 100 assessment was driven largely through revenues earned from sustainable sources.
  • Corporate Knights also recognized Manulife's strong long-term focus on diversity at the Board and executive management levels, and in connecting sustainability to compensation and performance.
  • In addition to being named to this year's Global 100, Manulife has also been recognized by Corporate Knights as one of Canada's Top 50 Companies for the last three years.

DEADLINE ALERT for PAYC, ILMN, and JRVR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Tuesday, January 9, 2024
Law, Suite, Investment, Cannibalization, GRAIL, Paycom, Complaint, Icahn, Defendant, Security (finance)

LOS ANGELES, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)

Retrieved on: 
Monday, January 8, 2024
Professional Services, Class Action Lawsuit, Suite, Icahn, Acquisition, Court, Complaint, News, Law, Defendant, GRAIL, Cryptocurrency

If you are a shareholder who suffered a loss, click here to participate.

Key Points: 
  • If you are a shareholder who suffered a loss, click here to participate.
  • If you purchased or otherwise acquired Illumina securities during the Class Period, you may move the Court no later than January 9, 2024 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Illumina, Inc. (ILMN) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Monday, January 8, 2024
Telephone, NEXT, Icahn, LLP, Court, CLASS, COST, GRAIL, Cryptocurrency

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Illumina investors who were adversely affected by alleged securities fraud between September 21, 2020 and November 9, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    ILMN investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

ILLUMINA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Illumina, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, January 6, 2024
Telephone, Icahn, Acquisition, Person, Court, Complaint, News, P.C, Defendant, GRAIL, District court, Cryptocurrency

Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Then, on October 17, 2023, Carl Icahn (“Icahn”) filed a complaint against current and former directors of Illumina, alleging direct and derivative claims of breaches of fiduciary duty.
  • The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.